PERMITTER DE PERMITTER DE POSTABLE DE POST

Organization TC | 6 c. c. Bldg.Room Ram Sew U. S. DEPARTMENT OF COMMERCE COMMISSIONER FOR PATENTS

AN EQUAL OPPORTUNITY EMPLOYER

OFFICIAL BUSINESS

ALEXANDRIA, VA 22313-1450 IF UNDELIVERABLE RETURN IN TEN DAYS

P.O. BOX 1450

CHANGE STAN TO THE STAN TO THE STAN THE



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.

EXAMINER

ART UNIT

PAPER NUMBER

27

DATE MAILED:

This is a communication from the examiner in charge of your application. COMMISSIONER OF PATENTS AND TRADEMARKS

NOTICE OF ALLOWABILITY

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance and Issue Fee Due or other appropriate communication will be mailed in due course.
This communication is responsive to the RCE filled 1/15/04
The allowed claim(s) is/are 10 472-14
☐ The drawings filed on 2/5/01 are acceptable.
Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).
☐ All ☐ Some* ☐ None of the CERTIFIED copies of the priority documents have been
received.
received in Application No. (Series Code/Serial Number)
received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
*Certified copies not received:
Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).
A SHORTENED STATUTORY PERIOD FOR RESPONSE to comply with the requirements noted below is set to EXPIRE THREE MONTHS FROM THE "DATE MAILED" of this Office action. Failure to timely comply will result in ABANDONMENT of this application. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).
□ Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL APPLICATION, PTO-152, which discloses that the oath or declaration is deficient. A SUBSTITUTE OATH OR DECLARATION IS REQUIRED.
☐ Applicant MUST submit NEW FORMAL DRAWINGS
because the originally filed drawings were declared by applicant to be informal.
including changes required by the Notice of Draftperson's Patent Drawing Review, PTO-948, attached hereto or to Paper No.
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
including changes required by the proposed drawing correction filed on, which has been approved
including changes required by the proposed drawing correction filed on, which has been approved by the examiner.
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings.
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson.
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF
 including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s)
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). 23, 25, 4226
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). 23, 25, 4226 Notice of Draftsperson's Patent Drawing Review, PTO-948
including changes required by the proposed drawing correction filed on
including changes required by the proposed drawing correction filed on, which has been approved by the examiner. including changes required by the attached Examiner's Amendment/Comment. Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the reverse side of the drawings. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftperson. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. Any response to this letter should include, in the upper right hand corner, the APPLICATION NUMBER (SERIES CODE/SERIAL NUMBER). If applicant has received a Notice of Allowance and Issue Fee Due, the ISSUE BATCH NUMBER and DATE of the NOTICE OF ALLOWANCE should also be included. Attachment(s) Notice of References Cited, PTO-892 Information Disclosure Statement(s), PTO-1449, Paper No(s). 23, 25, 426 Notice of Draftsperson's Patent Drawing Review, PTO-948 Notice of Informal Patent Application, PTO-152 Interview Summary, PTO-413
including changes required by the proposed drawing correction filed on

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

NOTICE OF ALLOWANCE AND FEE(S) DUE

23117

7590

03/11/2004

NIXON & VANDERHYE, PC 1100 N GLEBE ROAD 8TH FLOOR ARLINGTON, VA 22201-4714 EXAMINER STUCKER, JEFFREY J

STOCKER, JEITKET

ART UNIT PAPER NUMBER

1648

DATE MAILED: 03/11/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/775,805	02/05/2001	Barton F. Haynes	1579-548	4002

TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS IMMUNOGENIC COMPOSITION

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	06/11/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
- □ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
- II. PART B FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

03/11/2004

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

or <u>Fax</u> (703) 746-4000

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)

NIXON & VANDERHYE, PC 1100 N GLEBE ROAD 8TH FLOOR ARLINGTON, VA 22201-4714

7590

23117

Note: A certificate of mailing can only be used for domestic mailings of the Fec(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO, on the date indicated below.

(Depositor's name)	
(Signature)	
(Date)	

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/775,805	02/05/2001	Barton F. Haynes	1579-548	4002

TITLE OF INVENTION: HUMAN IMMUNODEFICIENCY VIRUS IMMUNOGENIC COMPOSITION

APPLN. TYPE	SMALL ENTITY	ISSUE FE	E PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$0	\$1330	06/11/2004
EXAM	MINER	ART UNI	T CLASS-SUBCLASS		
STUCKER	, JEFFREY J	1648	424-192100		
CFR 1.363). ☐ Change of correspond Address form PTO/SB/1	ce address or indication of "Fe lence address (or Change of C 22) attached. ion (or "Fee Address" Indicati or more recent) attached. Use	orrespondence	2. For printing on the patent front pagnames of up to 3 registered patent agents OR, alternatively, (2) the name firm (having as a member a registered agent) and the names of up to 2 registromeys or agents. If no name is list will be printed.	attorneys or 1e of a single d attorney or 2stered patent	

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignce is identified below, no assignce data will appear on the patent. Inclusion of assignce data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment. (A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)

4a. The following fee(s) are enclosed:	gories (will not be printed on the patent);	governmen
☐ Issue Fee	☐ A check in the amount of the fee(s) is enclosed.	
☐ Publication Fee	☐ Payment by credit card. Form PTO-2038 is attached.	
☐ Advance Order - # of Copies	☐ The Director is hereby authorized by charge the required fee(s), or credit any over Deposit Account Number(enclose an extra copy of this form	payment, to
Director for Patents is requested to apply the Issue Fo	e and Publication Fee (if any) or to re-apply any previously paid issue fee to the application identified above.	
(Authorized Signature)	(Date)	

NOTE; The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. Alexandria, Virginia 23313-1450. SEND TO: Commissioner for Patents, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMIT THIS FORM WITH FEE(S)



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspio.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/775,805		02/05/2001	Barton F. Haynes	1579-548	4002
23117	7590	03/11/2004		EXAM	INER
NIXON & VA		YE, PC		STUCKER,	JEFFREY J
8TH FLOOR				ART UNIT	PAPER NUMBER
ARLINGTON,	VA 22201	1-4714		1648	
				DATE MAILED: 03/11/2004	1

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 58 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 58 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.



Application/Control Number: 09/775,805

Art Unit: 1648

This Notice of Allowability is in response to the RCE filed 2/5/04. Claims 10 and 12-14 are pending and allowable.

The following is an Examiner's Statement of Reasons for Allowance:

The plethora of prior art supplied by applicant does not appear teach or suggest the claimed peptide.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Papers related this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG (November 15, 1989).

The Group 1600 Official Fax number is: (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Tech Center representative whose telephone number is (571)-272-1600.

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey Stucker whose telephone number is (571)-272-0911. The examiner can normally be reached Monday to Thursday from 7:00am-3:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (571)-272-0902.

JEFFREY STUCKER PRIMARY EXAMINER aneer. 1 of 2

Atty. Docket No.

Serial No.

INFORMATION DISCLOSURE CITATION

1579-548 Applicant

09/775.805

(Use several sheets if necessary)

HAYNES et al Filing Date

Group

February 5, 2001

1648

		U.S.	PATENT DOCUMENTS		_	
XAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
10	5,030,449	7/1991	Berzofsky et al		1	
/1	5,853,978	12/1998	Berman et al			*
	5,864,027	1/1999	Berman			
	5,932,218	8/1999	Berzofsky et al			
	5,939,074	8/1999	Berzofsky et al			-
	6,042,836	3/2000	Berman et al		7	
1 7	6,290,963	9/2001	Fischinger et al		7	
	6,294,322	9/2001	Berzofsky et al	7	7	
	6,458,527	10/2002	Luciw et al			
	5,081,226	1/1992	Berzofsky et al		\/	
	5,336,758	8/1994	Berzofsky et al		X	
24	5,622,703	4/1997	Berzofsky et al			
	5,695,762	12/1997	Berzofsky et al			
	5,711,947	1/1998	Berzofsky et al	/		
	5,820,865	10/1998	Berzofsky et al	7		
	5,882,853	3/1999	Berzofsky et al			
	5,976,541	11/1999	Berzofsky et al			
	5,980,899	11/1999	Berzofsky et al			
1	5,997,869	12/1999	Goletz et al			
	6,214,347	4/2001	Berzofsky et al			
	6,592,872	7/2003	Klimpel et al		1	

			, /-(1 C11)				
+						ENCLISHA	STRAC
	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YE\$ √	NO
18	WO 93/04697	3/1993	WIPO			` <u>`</u>	
71	WO 94/26785	11/1994	WIPO				
	WO 94/28929	12/1994	WIPO				
	WO 94/29339	12/1994	WIPO			·	
	WO 98/01564	1/1998	WIPO				
	WO 02/08716	1/2002	WIPO			X	
	WO 2002/20554	3/2002	WIPO				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

Ahlers, et al., "Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes After Two.

Immunizations", The Journal of Immunology, Vol. 150, No. 12, pp. 5647-5665 (1993)

Ahlers, et al., "Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, All Using the Same Adjuvant Immunization", AIDS Research and Human Retroviruses, Vol. 12, Number 4, pp. 259-272 (1996)

Berzofsky, et al., "Antigenic Peptides Recognized by T lymphocytes from AIDS Viral Envelope-Immune Humans"

Nature, Vol. 334, pp. 706-708 (1988)

aminer

ed, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include Examiner: Initial if per copy of this form with next communication to application.

न्यु च्या चढ्ड व्यव भा	Any, Docket No.	Serial No.
NFORMATION DISCLOSURE	1579-548	09/775,805
CITATION	Applicant	
(Use several cheets if necessary)	HAYNES et al	Graup
	February 5, 2001 1648	
		for Synthetic Peptides of gp 160 in HIV-Seropositive
	11 IMMINAIAEV. VAI 146. NA. 7. NA 7	'/ He/// Y 199
Hart, et al., "Priming of an	of Immunology, Vol. 146, No. 7, pp. 2 Anti-Human Immunodeficiency Viru Proc. Natl. Acad. Sci. USA, Vol. 88, p	s (HIV) CD8* Cytotoxic T Cells In Vivo by Carrier-Free
Hart, et al., "Priming of an HIV Synthetic Peptides", F Haynes, et al., "Conversion Tolerogen in Chimpanzees	Anti-Human Immunodeficiency Viru Proc. Natl. Acad. Sci. USA, Vol. 88, p a of an Immunogenic Human Immuno by the Fusogenic Domain of HIV gp	s (HIV) CD8* Cytotoxic T Calls In Vivo by Carrier-Free p. 9448-9452 (1991)
Hart, et al., "Priming of an HIV Synthetic Peptides", F Haynes, et al., "Conversion Tolerogen in Chimpanzees Medicine, Vol. 177, pp. 71 Haynes, et al., "Induction of Synthetic gp120 Envelope	Anti-Human Immunodeficiency Viru Proc. Natl. Acad. Sci. USA, Vol. 88, p of an Immunogenic Human Immuno by the Fusogenic Domain of HIV gp 7-727 (1993) of HIVMN Neutralizing Antibodies in Peptides", The Journal of Immunolog	s (HIV) CD8* Cytotoxic T Cells In Vivo by Carrier-Free p. 9448-9452 (1991) deficiency Virus (HIV) Envelope Synthetic Peptide to a 41 Envelope Protein", The Journal of Experimental Primates Using a Prime-Boost Regimen of Hybrid y, Vol. 151, No. 3, pp. 1646-1653 (1993)
Hart, et al., "Priming of an HIV Synthetic Peptides", Haynes, et al., "Conversion Tolerogen in Chimpanzees Medicine, Vol. 177, pp. 71 Haynes, et al., "Induction of Synthetic gp120 Envelope Hosmalin, et al., "Priming Glycoprotein of HIV-1 in I	Anti-Human Immunodeficiency Virus Proc. Natl. Acad. Sci. USA, Vol. 88, per of an Immunogenic Human Immunogenic Human Immunogenic Domain of HIV gp. 7-727 (1993) of HIVMN Neutralizing Antibodies in Peptides", The Journal of Immunology with T Helper Cell Epitope Peptides I Primates", The Journal of Immunology	s (HIV) CD8* Cytotoxic T Cells In Vivo by Carrier-Free p. 9448-9452 (1991) deficiency Virus (HIV) Envelope Synthetic Peptide to a 41 Envelope Protein", The Journal of Experimental Primates Using a Prime-Boost Regimen of Hybrid y, Vol. 151, No. 3, pp. 1646-1653 (1993) Enhances the Antibody Response to the Envelope y, Vol. 146, No. 5, pp. 1667-1673 (1991)
Hart, et al., "Priming of an HIV Synthetic Peptides", Haynes, et al., "Conversion Tolerogen in Chimpanzees Medicine, Vol. 177, pp. 71 Haynes, et al., "Induction of Synthetic gp120 Envelope Hosmalin, et al., "Priming Glycoprotein of HIV-1 in 1 Liao, et al., "Increased Lumwith Monephosphoryl Lipi	Anti-Human Immunodeficiency Virus Proc. Natl. Acad. Sci. USA, Vol. 88, per of an Immunogenic Human Immunote by the Fusogenic Domain of HIV gp. 7-727 (1993) of HIVMN Neutralizing Antibodies in Peptides", The Journal of Immunolog with T Helper Cell Epitope Peptides I Primates", The Journal of Immunolog munogenicity of HIV Envelope Subunid A and GM-CSF", Vaccine, Vol. 20,	s (HIV) CD8* Cytotoxic T Calls In Vivo by Carrier-Free p. 9448-9452 (1991) deficiency Virus (HIV) Envelope Synthetic Peptide to a 41 Envelope Protein", The Journal of Experimental Primates Using a Prime-Boost Regimen of Hybrid y, Vol. 151, No. 3, pp. 1646-1653 (1993) Inhances the Antibody Response to the Envelope y, Vol. 146, No. 5, pp. 1667-1673 (1991) it Complexed with a ₂ -Macroglobulin When Combined

aminer Date Considered 3/8/04

Exeminer: Initial if reference considered whether or not citation is in conformance with MPEP 608; Draw line through citation if not/in conformance and not considered. Include copy of this form with next communication to application.

ORN	MATION DISCLOS	JRE ATTY. DOCKE	T NO.	SERIAL NO.		
•	CITATION	1579-548		09/775,805		
		APPLICANT				
- ē		HAYNES	et al			
(Use	several sheets if necessary)	FILING DATE		GROUP		
		February	5, 2001	1648		
		U.S. PA	TENT DOCUMENTS		· · · · · · · · · · · · · · · · · · ·	
XAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
M	5,976,551	11/1999	Mottez et al	- 02/00	- OUBOLAGG	AFFRORKIA
	1				<u> </u>	
<i>V</i>						
					-	
				-		
					1	
	(1)					
		▼ FOREIGN	PATENT DOCUMENT	rs		
	DOCUMENT	7				TRANSLATION
···	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	YES NO
1	WO 96/41189	12/1996	WIPO			
						·
						, ,
	OTUED DOCUM	AENTO (:			L	
	Hale et al "T Coll M	Ultidatorminant Pa	ing Author, Title, Date gions in the Human Immuno	, Pertinent pa	ages, etc.)
	Overcoming the Pro	blem of Maior Hist	ocompatibility Complex Rest	triction" Internati	E⊓velope: ional Immur	i oward pology 1/4):40
1	<u>(</u> 415 (1989)					
	Loktev et al, "Desigr	of immunogens a	s components of a new gen	eration of molect	ılar vaccine	s", Journal of
// 	Biotechnology 44(1)	(129-137 (1996)				
₩					· · · · · · · · · · · · · · · · · · ·	
					······································	
				*		
					·	
	\					
		<u></u>				
aminer			Date Considered			
miner: Initia	I if reference considered, whether with next communication to appl	or not citation is in confor	mance with MPEP 609; Draw line throug	h citation if not in confo	rmance and not	considered. Include
y or uns torm	with next conjugation to appl	Cayoy.				A820 (Also PTO-14
	Seffren X	MUCKELN !	3/8/04			7.020 (AlSO F 10-14
		and the second	7 4 7	***************************************		

NFORMATION DISCLOSURE

CITATION

(Use several sheets if necessary)

Attv.	Docke	t No.	

Serial No.

1579-548 Applicant

09/775,805

HAYNES et al

Group

February 5, 2001

1648

FOREIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994)								
POPEIGN PATENT DOCUMENTS FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed.), Raven Press, Ltd., New York, pgs. 185-209 (1994)				U.S. PATENT DOCUMENTS			FILING	DATE
FOREIGN PATENT DOCUMENTS TRANSLATION DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, 'Is Antigenic Variation of HIV Important for AID's and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer ###################################	*EXAMINER	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	IF APPRO	PRIATE
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April	- IIIIIAE	V .			<u> </u>			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April					 			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April					 			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April		 			+	 		
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April		 						
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April	· ·				1			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April					 			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April					 			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April		 	-		 			
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April			1					
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April								
DOCUMENT DATE COUNTRY CLASS SUBCLASS YES NO OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer April			500	CION DATENT DOCUMENTS		L		
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer miner: Initial if reference Considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include			FOR	EIGN PATENT DOCUMENTS			TRANSL	ATION
OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.) Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer physical Considered whither or not citation is in conformance with MPEP 606, Draw line through citation if not in conformance and not considered. Include		DOOUNENT	DATE	COLINTRY	CLASS	SUBCLASS		
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		DOCUMENT	DATE	COUNTRY	T	1		
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		 \ 			†	<u> </u>		
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		 	<u> </u>					
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
Wain-Hobson, "Is Antigenic Variation of HIV Important for AIDS and What Might Be Expected in the Future?", The Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer xaminer January Market Considered miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include					<u> </u>	<u></u>		54
Evolutionary Biology of Viruses. Stephen S. Morse (ed), Raven Press, Ltd., New York, pgs. 185-209 (1994) xaminer miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		OTHER DOCL	JMENTS (in	cluding Author, Title, Date, Pertinent	pages, et	tc.)		
xaminer Additional State Considered Springered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include	1	Wain-Hobson, "Is Antig	genic Variation	n of HIV Important for AIDS and What Mig	ght Be Exp	ected in the L	outure?",	The
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		Evolutionary Biology of	viruses. Stej	onen 5. Morse (ed), Raven Press, Ltd., New	TOIK, pgs	. 103-209 (13	794)	
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include	/ - 		<u> </u>					
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include		\	11					
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include								
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include			1					
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include	<u>j </u>	11111	1/1	1.6/2				··
miner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include	Examiner	Jeffry M	ucker	2 8/04 Date Considered				
	aminer: Initial if	reference considered, whether or	r not citation is in	conformance with MPEP 609; Draw line through citation	if not in confo	rmance and not o	considered.	Include